Xilio Therapeutics (NASDAQ:XLO) Trading 2.8% Higher

Xilio Therapeutics, Inc. (NASDAQ:XLOGet Rating) traded up 2.8% on Tuesday . The company traded as high as $2.97 and last traded at $2.88. 11,376 shares were traded during mid-day trading, a decline of 60% from the average session volume of 28,583 shares. The stock had previously closed at $2.80.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Chardan Capital assumed coverage on Xilio Therapeutics in a research note on Wednesday, December 21st. They issued a “buy” rating and a $7.00 price objective for the company. Raymond James dropped their price objective on Xilio Therapeutics from $31.00 to $13.00 and set an “outperform” rating for the company in a research note on Thursday, November 10th. Finally, Guggenheim lowered their target price on Xilio Therapeutics to $15.00 in a research note on Tuesday, November 15th.

Xilio Therapeutics Trading Up 2.8 %

The stock has a market capitalization of $79.05 million and a PE ratio of -0.85. The company has a 50 day simple moving average of $2.53 and a 200 day simple moving average of $2.59. The company has a current ratio of 8.45, a quick ratio of 8.45 and a debt-to-equity ratio of 0.04.

Xilio Therapeutics (NASDAQ:XLOGet Rating) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.17. Analysts predict that Xilio Therapeutics, Inc. will post -3.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xilio Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Xilio Therapeutics by 112.7% during the third quarter. Vanguard Group Inc. now owns 891,533 shares of the company’s stock worth $2,595,000 after purchasing an additional 472,368 shares in the last quarter. Laurion Capital Management LP bought a new position in shares of Xilio Therapeutics in the 2nd quarter valued at about $417,000. State Street Corp grew its position in shares of Xilio Therapeutics by 58.5% in the 1st quarter. State Street Corp now owns 93,861 shares of the company’s stock valued at $664,000 after acquiring an additional 34,651 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Xilio Therapeutics during the 2nd quarter worth about $220,000. Finally, Millennium Management LLC acquired a new stake in shares of Xilio Therapeutics during the 2nd quarter worth about $146,000. 60.46% of the stock is currently owned by hedge funds and other institutional investors.

About Xilio Therapeutics

(Get Rating)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.

Recommended Stories

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.